Answers are grounded in this paper and cite their sources.
The recently introduced human papillomavirus (HPV) prophylactic vaccines are the first widely approved vaccines specifically designed to prevent a sexually transmitted infection and are only the second (after the hepatitis B virus vaccine) designed to prevent human cancer, in this case cervical cancer and several other anogenital and head and neck cancers. The antigens in the HPV vaccines are naked icosohedral virus-like particles (VLPs) composed of the major HPV virion protein L1. These subunit vaccines were independently developed and tested by 2 companies, GlaxoSmithKline (GSK) and Merck [1]. The GSK vaccine, Cervarix, is bivalent—it contains the VLPs of HPV-16 and -18, the types that cause ∼70% of cervical cancers worldwide—and is produced in insect cells. Cervarix also contains the proprietary adjuvant AS04, which is composed of monophyosphoryl lipid A and an aluminum salt. The Merck vaccine, Gardasil, is tetravalent—it contains the HPV-16 and -18 VLPs and the VLPs of HPV-6 and -11, which cause 80%–90% of genital warts—and is produced in yeast. Gardasil is adjuvanted with a simple aluminum salt. The vaccines are delivered by intramuscular injection in 3 doses over 6 months. Both have been remarkably effective in phase 3 trials conducted in young women, providing nearly complete protection against persistent genital tract infection and premalignant neoplastic disease end points caused by the HPV types targeted by the respective vaccines [2]. Both vaccines have been licensed in >50 countries, starting with Merck’s in 2006 and GSK’s in 2007, and millions of doses have been sold. However, despite the rapid and successful introduction of these 2 vaccines, they can reasonably be viewed as introductory products that will likely be followed by second-generation vaccines that will target more types and/or be less expensive to produce and deliver. This article will focus on one aspect of HPV VLP vaccines, the assessment of immunogenicity
No takes yet. Share an insight, caveat, or question.
Schiller et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: